Gene Mapping, Cloning, and Sequencing
Isolation and mapping of the human EIF4A2 gene homologous to the murine protein synthesis initiation factor 4A-II gene Eif4a2Sudo K.a,b · Takahashi E.c · Nakamura Y.a,d
aDepartment of Biochemistry, Cancer Institute, Tokyo, bMitsubishi Kagaku BCL Co. Ltd., Itabashi, Tokyo, cDivision of Genetics, National Institute of Radiological Sciences, Chiba, and dLaboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
We report isolation of human cDNA highly homologous to murine Eif4a2, a gene for one of the protein-synthesis initiation factors involved in the binding of mRNA to the ribosome. This cDNA, which encodes a 407-amino-acid protein, belongs to a highly-conserved gene family, the DEAD-box gene family. The human homologue of Eif4a2 was expressed in all normal tissues examined, but in variable amounts, being highly expressed in skeletal muscle and ovary, and less abundantly in liver, kidney, and pancreas. Furthermore, we have localized the human EIF4A2 to chromosome 18p11.2 by fluorescent in situ hybridization.
© 1995 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.